The Effects of a Relapse Prevention Program with Individual Motivational Interview on Relapse and Readmission among Patients with Schizophrenia and Substance Use Disorders
Article Sidebar
Main Article Content
Abstract
Objective: To examine the effects of a relapse prevention program combined with individual motivational interview among schizophrenia patients with substance use disorders.
Materials and methods: This quasi-experimental study utilized a two-group repeated measures design. The sample consisted of 76 schizophrenia patients with substance use disorders who had been readmitted within 28 days. Participants were randomly assigned to either the experimental group (n = 38) and a control group (n = 38). The experimental group received a 2-week program comprising six sessions (3 times/week, 45–60 minutes/session), whereas the control group received standard care. Outcomes were evaluated at pre-test, post-test, and during follow-ups at 1 and 4 weeks post-discharge using the Intent to Prevent Relapse Questionnaire, the Drug Prevention Behavior Scale, and the Time Line Follow Back (TLFB). Data were collected from October 14, 2025, to March 31, 2026, and analyzed using descriptive statistics, Chi-square test, and repeated measures ANOVA.
Results: : The experimental group exhibited a significantly higher intention for relapse prevention (F(1.368, 49.253) = 1286.118, p < .05, partial η² = 0.973) and greater drug prevention behavior (F(1.732, 62.356) = 632.360, p < .05, partial η² = 0.946) compared to the control group. Additionally, the experimental group experienced significantly lower rates of substance relapse within both 7 and 30 days (p < .05), as well as reduced rates of psychiatric hospital readmission within 28 days (p < .05) compared to the control group.
Conclusion: The relapse prevention program combined with individual motivational interview is effective in reducing substance relapse among schizophrenia patients with substance use disorders.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความหลังผ่านการปรับแก้จากกองบรรณาธิการแล้ว เป็นลิขสิทธ์ของวารสารจิตเวชวิทยาสาร โรงพยาบาลสวนปรุง กรมสุขภาพจิต กระทรวงสาธารณสุข ห้ามเผยแพร่เพื่อประโยชน์ทางการค้าโดยไม่ได้รับอนุญาต แต่อนุญาตให้เผยแพร่บทความดังกล่าวเพื่อประโยชน์ทางการศึกษาแก่ประชาชนทั่วไป ทั้งนี้กองบรรณาธิการไม่จำเป็นต้องเห็นด้วยกับบทความหรือข้อคิดเห็นใดๆ ที่ปรากฏในวารสารสวนปรุง
References
Szerman N, Torrens M, Maldonado R, Balhara YPS, Salom C, Maremmani I, et al. Addictive and other mental disorders: A call for a standardized definition of dual disorders. Transl Psychiatry. 2022;12(1):446. doi:10.1038/s41398-022-02212-5.
Taggart N, Kinner SA, Young JT. The prevalence and correlates of dual diagnosis among adults in custody: A systematic review and meta-analysis. Drug Alcohol Depend. 2025;272:111512. doi:10.1016/j.drugalcdep.2024.111512.
Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234-58. doi:10.1016/j.drugalcdep.2018.07.011.
Burrell Ward H, Nemeroff CB, Carpenter L, Grzenda A, McDonald WM, Rodriguez CI, et al. Substance use disorders in schizophrenia: Prevalence, etiology, biomarkers, and treatment. Personal Med Psychiatry. 2023;39-40:100103. doi: 10.1016/j.pmip.2023.100103.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511-8. doi:10.1001/jama.1990.03450190043026.
Ministry of Public Health. Health Data Center (HDC) [Internet]. Nonthaburi: Ministry of Public Health; 2025 [cited 2026 Jun 2]. Available from: https://hdc.moph.go.th
Temmingh H, Susser E, Mall S, Campbell M, Sibeko G, Stein DJ. Prevalence and clinical correlates of substance use disorders in South African Xhosa patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2021;56(4):695-706. doi: 10.1007/s00127-020-01942-5.
Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, Hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(1):40-8. doi: 10.1016/S2215-0366(15)00357-0.
Bouchard M, Lecomte T, Cloutier B, Herrera-Roberge J, Potvin S. Dropout Rates in Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse: A Systematic Review and Meta-Analysis. Front Psychiatry. 2022;13:842329. doi: 10.3389/fpsyt.2022.842329.
Lieslehto J, Tiihonen J, Lähteenvuo M, Tanskanen A, Taipale H. Primary nonadherence to antipsychotic treatment among persons with schizophrenia. Schizophr Bull. 2022;48(3):655-63. doi: 10.1093/schbul/sbac014.
Neyra A, Parro-Torres C, Ros-Cucurull E, Carrera I, Echarri E, Torrens M. Management of schizophrenia and comorbid substance use disorders: expert review and guidance. Ann Gen Psychiatry. 2024;23(1):40. doi: 10.1186/s12991-024-00529-7.
Nilaban S, Sriherun B, Kongthong U. Causal relationship of factors affect relapsing behavior of methamphetamine. J Grad Stud Valaya Alongkorn Rajabhat Univ. 2016;10(1):82-4. (in Thai).
Salahuddin NH, Herlitzius E, Schütz A, Siafis S, Priller J, Leucht S, et al. Psychological and psychosocial interventions for people with schizophrenia and co-occurring substance use disorders: A systematic review and meta-analysis. JAMA Psychiatry. 2026;83(4):353-62. doi: 10.1001/jamapsychiatry.2025.4390.
Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2008;34(1):123-38. doi: 10.1016/j.jsat.2007.01.004.
Substance Abuse and Mental Health Services Administration. Chapter 5: Strategies for Working With People Who Have Co-Occurring Disorders. In: Substance Use Disorder Treatment for People With Co-Occurring Disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2020 [cited 2026 Jul 20]. (Treatment Improvement Protocol (TIP) Series, No. 42). Available from: https://www.ncbi.nlm.nih.gov/books/NBK571013/
Siddiqui S, Mehta D, Coles A, Selby P, Solmi M, Castle D. Psychosocial interventions for individuals with comorbid psychosis and substance use disorders: systematic review and meta-analysis of randomized studies. Schizophr Bull. 2024;50(4):sbae101. doi: 10.1093/schbul/sbae101.
Somdet Chaopraya Institute of Psychiatry, Nursing Department for Psychiatric Substance Abuse Patients. Annual report of nursing department for psychiatric substance abuse patients, Somdet Chaopraya Institute of Psychiatry 2026. Bangkok: Somdet Chaopraya Institute of Psychiatry; 2026.
Uten K, Ratsamesuwiwat J, Yasin W, Kumlue W, Srisuwan P. The development of integrative program on relapse prevention among persons with amphetamine induced psychotic disorder. J Psychiatr Nurs Ment Health. 2022;36(3):1-15. (in Thai).
Morrens M, Dewilde B, Sabbe B, Dom G, De Cuyper R, Moggi F. Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. Eur Addict Res. 2011;17(3):154-63. doi: 10.1159/000324864.
Miller WR, Rollnick S. Motivational interviewing: Helping people to change and grow. 4th ed. New York: Guilford Press; 2023.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24(1):97-9.
Andersen J, Larsen J, Kørner A, Nielsen B, Schultz V, Behnke K, et al. The Brief Psychiatric Rating Scale: Schizophrenia, reliability and validity studies. Nord Psykiatr Tidsskr. 1986;40(2):135-8. doi: 10.3109/08039488609096456.
Saengduanchai K. Effects of a cognitive behavioral therapy program combined with social support on readiness to prevent relapse and non-relapse behaviors of alcohol-dependent patients [dissertation]. Bangkok: Srinakharinwirot University; 2010.
Chinaketu S. Factors affecting drug prevention behaviors of vocational certificate students under the Office of Vocational Education in Ratchaburi Province [master's thesis]. Nakhon Pathom: Silpakorn University; 2010.
Suwannachot K. Effectiveness of a brief motivational enhancement and cognitive behavioral therapy group on relapse among methamphetamine-dependent patients with psychiatric co-morbidities at a psychiatric hospital in Southern Thailand [dissertation]. Bangkok: Chulalongkorn University; 2010.
Herz MI, Lamberti JS, Mintz J, Scott R, O'Dell SP, McCartan L, et al. A program for relapse prevention in schizophrenia: a controlled study. Arch Gen Psychiatry. 2000;57(3):277-83. doi: 10.1001/archpsyc.57.3.277.
Rømer Thomsen K, Thylstrup B, Pedersen MM, Pedersen MU, Simonsen E, Hesse M. Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders. Schizophr Res. 2018;195:495-500. doi:10.1016/j.schres.2017.09.026.
Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, et al. Integrated motivational interviewing and Cognitive Behavior Therapy for people with psychosis and comorbid Substance misuse: Randomized controlled trial. BMJ. 2010;341:c6325. doi: 10.1136/bmj.c6325.
Junsirimongkol B, Suriyachai S, Withayathawornwong L, Darakorn Na Ayodthaya P, Kornkumjairit K, Kunarak A. The effect of integrated co-occurring psychiatric substance and alcohol use disorders rehabilitation program (ICOD-R) on drinking behavior and psychotic symptom in co-occurring disorder patients. Bangkok: Somdet Chaopraya Institute of Psychiatry; 2014.
Wang W, Chau AKC, Kong P, Sun X, So SH. Efficacy of Motivational Interviewing in Treating Co-occurring Psychosis and Substance Use Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2021;83(1):21r13916. doi: 10.4088/JCP.21r13916.
DiClemente C, Nidecker M, Bellack A. Motivation and the stages of change among individuals with severe mental illness and substance abuse disorders. J Subst Abuse Treat. 2008;34(1):25-35. doi: 10.1016/j.jsat.2006.12.034.
Mueser KT, Glynn SM, Cather C, Xie H, Zarate R, Smith LF, et al. A randomized controlled trial of family intervention for co-occurring substance use and severe psychiatric disorders. Schizophr Bull. 2013;39(3):658-72. doi: 10.1093/schbul/sbr203.
Chantrasaen A, Uthis P, Suktrakul S. Effects of family psychoeducation on severity of psychiatric symptoms in patients with schizophrenia using amphetamine. J Mental Health Psychiatr Nurs. 2019;33(3):30-58. (in Thai).
Wittayathawornwong L, Junsirimongkol B, Suriyachai S, Darakorn Na Ayutthaya P, Kornkamchairit K, Khunarak U. The effect of the integrated program on drinking behavior and psychotic symptoms in alcohol use disorders with co-occurring disorders patients. J Psychiatr Nurs Ment Health. 2016;30(2):143-54. (in Thai).
Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 2001;158(10):1706-13. doi: 10.1176/appi.ajp.158.10.1706.
Kuntsche S, Vuong A, Cloud Z, Cosgrove M, Pradel M, Hameed M, et al. Family-inclusive approaches in the context of a dual diagnosis: A systematic review of relational and individual wellbeing outcomes. Clin Psychol Rev. 2026;128:102811. doi: 10.1016/j.cpr.2026.102811.
Magill M, Helminen EC, Lynch-Gadaleta B, Allen K, Kiluk BD, et al. Cognitive-behavioral interventions for co-occurring substance use and mental health disorders. Drug Alcohol Depend. 2025;274:112756. doi: 10.1016/j.drugalcdep.2025.112756.
Mihretu A, Fekadu A, Alemu AA, Hanlon C. Psychosocial interventions for people with comorbid substance use disorders in people with severe mental health conditions in low- and middle-income countries: scoping review. BJPsych Open. 2025;11(6):e222. doi: 10.1192/bjo.2025.10840.
McGovern MP, Wrisley BR, Drake RE. Relapse of substance use disorder and its prevention among persons with co-occurring disorders. Psychiatr Serv. 2005;56(10):1270-3. doi: 10.1176/appi.ps.56.10.1270.
